Dr. Pusztai Discusses DNA Abnormalities in Breast Cancer
Lajos Pusztai, MD, PhD, Yale Cancer Center, discusses DNA abnormalities in breast cancer.
Pusztai says there are only three types of abnormalities that oncologists can pick up. The best examples of FDA-approved drugs for breast cancer are HER2-amplification and HER2-targeted therapies, such as trastuzumab.
Some abnormalities have also been successfully targeted in other diseases, such as EGFR mutations, which can be targeted with gefitinib in lung cancer.
A common and important question is whether or not the abnormalities in breast cancer confer the same degree of sensitivity to a targeted drug, as they do in other disease types, says Pusztai.
Lajos Pusztai, MD, PhD, professor of medicine (medical oncology), chief of Breast Medical Oncology, co-director, Cancer Genetics Research Program, Yale Cancer Center, discusses DNA abnormalities in breast cancer.
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
